{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
LP-20 (1-[2-(4-Methoxyphenyl)phenyl]piperazine) is a potent serotonin 5-HT7 receptor antagonist with a low binding affinity for the 5-HT1A and adrenergic 1 receptor. In animal models
LP-20 was investigated as a potential positron emission tomography (PET) radiotracer, due to high synthetic availability of 11C radiolabeled compound. Although [11C] LP-20 exhibited in vitro binding with 5-HT7, moderate brain uptake and relatively stable metabolism in the brain, in vivo evaluation showed limited specificity of [11C] LP-20 for 5-HT7.
Status:
Possibly Marketed Outside US
First approved in 2012
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Stearamine is an aliphatic amine intended for use in cosmetic formulations as antistatic agent. In cosmetics and personal care products, Lauramine and Stearamine have been used in hair preparations. Stearamine is also used as a corrosion-inhibiting boiler-water additive. Stearamine has antimicrobial properties. Stearylamine has been shown to prevent drug (lansoprazole) degradation and maintained drug stable in nanostructured lipid carriers (NLCs). Stearamine is used as positive charge inducing agent in different pharmaceutical formulations. Thus, the presence of stearylamine reduced the permeability coefficient for the cationic species of the drugs by approximately an order of magnitude, but had no effect on the neutral species of the drugs. The efflux curves observed for both verapamil and prochlorperazine could be mathematically modeled by assuming that the primary influence of stearylamine was on the development of a positive surface charge density on the inner monolayer of the liposome. Taken in sum, these results indicate that stearylamine is effective at decreasing the leakage of cationic drugs from liposomes, and may prove to be a valuable component of liposomal drug formulations.
Status:
Possibly Marketed Outside US
Source:
Teoremac by Sanfer
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Glucametacin is a non-steroidal anti-inflammatory, analgesic, antipyretic agent. Glucametacin was compared with ketoprofen in a double-blind, crossover trial. The drugs were given in total daily doses of 420 mg glucametacin and 300 mg ketoprofen for 20 days to 30 patients with chronic arthropathies of an inflammatory or degenerative nature. Both drugs were well tolerated and resulted in significant improvements in a number of criteria of disease assessment. Although there were no significant differences between results seen with the two drugs, there appeared to be trends in favour of glucametacin in respect to both efficacy and tolerance.
Status:
Possibly Marketed Outside US
Source:
NCT03833089: Phase 4 Interventional Active, not recruiting Ventricular Arrhythmias and Cardiac Arrest
(2019)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 349
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 349
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M006
(2024)
Source URL:
First approved in 2012
Source:
21 CFR 358H
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 333C
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2014)
Source URL:
First approved in 2012
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
NCT03775876: Phase 4 Interventional Completed Hemodynamic
(2017)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (MIXED)